I answered this earlier as well. From another poster.
None of those are the same thing. Car-T is definitely NOT a vaccine, it's an engineered cell that attacks in a specific manner, typically so far against a particular antigen. But it is definitely NOT in any form currently approved, a "vaccination". That is part of the problem with Car-T, many patients have recurrences of cancer. It's a powerful scalpel, and there may be some induced immunity as the body indirectly then can have a better chance of fighting off a mutation. But Car-T itself is engineered to kill cancer cells in the moment of injection, and originally the engineered tumor killing cells were not intended to stick around though there may be some evidence that for some patients that may be the case now. But again, still the real problem is, recurrence. It's a very expensive treatment, in that instance.
Provenge attacks one antigen.
BCG. is basically a tuberculosis treatment / vaccine that works for bladder cancer so long as it is still in the bladder. Again, it seems to indirectly work against that cancer, but it is not a general cancer vaccine and has no potential for that as a feature. It does not treat bladder cancer that has spread to other parts of the body.
So the difference for DCVax. DCVax is a customized cancer vaccine for EACH PATIENT'S specific cancer. Right now it is for glioblastoma but has potential to be a platform that will inoculate patients for solid tumors in any part of the body, and to find antigens even of which we are not aware, because it is personalized and customized to each patient's tumor and uses the bodies own immune system to identify the mutations and parts that do not belong in that patient's cells generally.
Making these simplistic comparisons without really delving into each type of treatment really defeats the purpose of having a conversation. I can see how it can impact low information, easily discouraged newbies, but I'd expect people who discuss this on a daily basis to see the differences quite bit more clearly.
